Ipamorelin
Other ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Synthetic growth hormone secretagogue studied for pharmacology and postoperative ileus. FDA flags immunogenicity/impurity concerns and serious adverse events in an intravenous gastric-motility study.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This safety record covers a controlled, investigational, or otherwise out-of-scope substance. It remains available for reference, but it is not part of NutriStack's public supplement publication set.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Ipamorelin is an other most often used for no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. NutriStack rates the overall evidence as insufficient. A typical adult dose is Not provided; NutriStack does not provide dosing guidance for research peptides., commonly taken as not supported for human use outside approved clinical research or regulated medical care. This profile indexes 3 sources.
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
The bottom line
Evidence rating insufficient. Most-documented uses: no approved wellness use, human efficacy evidence is insufficient for consumer guidance, reference-only safety profile. 3 sources indexed (1999–2026), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Ghrelin receptor agonist that stimulates growth hormone release. This endocrine and GI-motility activity is not equivalent to proven safe wellness or body-composition use.3,1
Dosing & protocol.
Route-specific guidance is intentionally not provided for unapproved research peptides.
Full safety detail.
Side effects
- Unknown product purity, potency, and sterility risk outside regulated drug supply
- Injection-site reactions or infection risk with injectable products
- Immune reactions are possible with peptide impurities or aggregation
Contraindications
- Pregnancy or nursing
- History of cancer or active malignancy unless specifically cleared by an oncologist
- Use by competitive athletes subject to anti-doping rules
- Use without clinician supervision
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
1- 1Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsSource linkedPMIDBeck DE et al. · Int J Colorectal Dis · 2014
Clinical trial context was postoperative ileus, not consumer GH or recovery use.
Reference material
2- 2Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksSource linkedURLU.S. Food and Drug Administration · FDA · 2026
FDA flags immunogenicity/impurity concerns, unnatural amino-acid characterization complexity, serious adverse events including death in an IV gastric-motility study, and insufficient route-specific safety data.
- 3Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteersSource linkedPMIDGobburu JV et al. · Pharm Res · 1999
Human volunteer PK/PD study confirms growth hormone releasing activity but does not establish wellness efficacy.
Common questions.
Quick answers about Ipamorelin, drawn from the data on this page.
What is Ipamorelin?
Synthetic growth hormone secretagogue studied for pharmacology and postoperative ileus. FDA flags immunogenicity/impurity concerns and serious adverse events in an intravenous gastric-motility study.
What is Ipamorelin used for?
Commonly cited benefits of Ipamorelin include: No approved wellness use; Human efficacy evidence is insufficient for consumer guidance; Reference-only safety profile. NutriStack rates the overall evidence as insufficient.
What is a typical dose of Ipamorelin?
A typical adult dose of Ipamorelin is Not provided; NutriStack does not provide dosing guidance for research peptides.. The commonly recommended form is Not supported for human use outside approved clinical research or regulated medical care. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Ipamorelin?
Reported side effects include unknown product purity, potency, and sterility risk outside regulated drug supply, injection-site reactions or infection risk with injectable products, immune reactions are possible with peptide impurities or aggregation. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Ipamorelin?
NutriStack rates this as Insufficient, meaning the body of evidence reviewed in NutriStack's tiering framework. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Ipamorelin in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.